The purpose of this study is to evaluate changes of body composition induced by Sodium-glucose cotransporter-2 (SGLT2) inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).
Sodium-glucose cotransporter-2 (SGLT2) inhibitor increases urinary excretion of glucose, promoting glycemic control and weight loss. However, it is unclear whether weight loss is attributed to decrease in fat components and associated with favorable changes in metabolic profile. The purpose of this study is to evaluate changes of body composition induced by SGLT2 inhibitor and its metabolic consequence in Korean type 2 diabetes (T2D).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
200
addition of empagliflozin 10 MG
dose escalation of hypoglycemics oral
Seoul National University Bundang Hospital
Seongnam-si, Gyeonggi-do, South Korea
RECRUITINGHbA1c
glycemic control
Time frame: 6 months
Biochemical parameters
Ketone body concentration
Time frame: 6 months
Body weight
Weight change
Time frame: 6 months
Body fat
fat change
Time frame: 6 months
Systolic and diastolic blood pressures
blood pressure change
Time frame: 6 months
Lipid profile
Triglyceride
Time frame: 6 months
Insulin resistance
HOMA-IR
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.